recombinant meningococcal group B vaccine + meningococcal groups A, C, W, and Y conjugate vaccine

**Pentavalent meningococcal vaccine** combining a **recombinant protein-based serogroup B component** (typically factor H binding protein, FHbp) with a **conjugate vaccine against serogroups A, C, W, and Y**. It induces humoral and cellular immune responses by presenting meningococcal antigens—polysaccharide conjugates for ACWY serogroups and recombinant proteins for B—to stimulate protective antibodies against *Neisseria meningitidis*. Developed by **Pfizer** (Penbraya) and **Sanofi/GSK** (Penmenvy), it is **FDA-approved** for active immunization against invasive meningococcal disease caused by serogroups A, B, C, W, and Y in individuals aged 10-25 years, particularly recommended for healthy adolescents 16-23 years via shared clinical decision-making or those at increased risk (e.g., immunocompromised, asplenia, complement deficiencies, outbreaks, travel).[1][2][4]

Brand names

PenbrayaPenmenvy

Other names

Meningococcal groups A, B, C, W, and Y vaccine (5 strain)MenABCWY vaccineMenACWY-TT/MenB-FHbpMenACWY-CRM/MenB-FHbp